Core Viewpoint - C3.ai, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 26, 2025, and August 8, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that C3.ai's management provided misleading positive statements while concealing adverse facts about the company's growth, particularly regarding the health of its CEO and its impact on deal closures [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [2] - Following the announcement, C3.ai's stock price plummeted from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [2] Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request to be appointed as lead plaintiff in the class action lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - The C3.ai class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, particularly in relation to CEO Thomas M. Siebel's health concerns, which ultimately led to a significant drop in stock price following disappointing financial results [1][4][5]. Group 1: Lawsuit Details - The lawsuit is titled Liggett v. C3.ai, Inc. and is filed in the Northern District of California, seeking to represent purchasers of C3.ai securities [1]. - The complaint claims that C3.ai's optimistic financial projections were not reflective of reality and were overly dependent on the health of its CEO [4]. - Following the announcement of disappointing preliminary financial results for Q1 FY 2026 and a reduction in revenue guidance, C3.ai's stock price fell by more than 25% [5]. Group 2: Legal Process - Investors who suffered losses and wish to serve as lead plaintiff must file their motions by October 21, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [6]. Group 3: Company Background - C3.ai operates as an enterprise artificial intelligence application software company [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth and the impact of its CEO's health on the company's performance, leading to a significant drop in stock price following disappointing financial results [1]. Group 1: Allegations and Impact - The lawsuit claims that C3.ai's management made overly positive statements while concealing material adverse facts about the company's growth potential and the CEO's health issues [1]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health [1]. - Following the announcement, C3.ai's stock price plummeted from $22.13 per share to $16.47 per share, marking a decline of approximately 25.58% in just one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of C3.ai during the class period from February 26, 2025, to August 8, 2025, are encouraged to register for the class action lawsuit [2]. - The deadline for shareholders to seek lead plaintiff status is October 21, 2025, and there is no cost or obligation to participate in the case [2].

Core Insights - C3 AI has been recognized as a Leader in Verdantix's Green Quadrant: Industrial AI Analytics Software (2025) report, achieving the highest overall scores in capabilities and momentum [1] Group 1 - The report evaluates Enterprise AI analytics software vendors specifically in predictive maintenance and supply chain solutions [1] - C3 AI continues to demonstrate strong performance in the industrial AI analytics software market [1]

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects [1]. Group 1: PubMatic, Inc. (NASDAQ: PUBM) - The class period for PubMatic is from February 27, 2025, to August 11, 2025, with a lead plaintiff deadline of October 20, 2025 [2]. - Allegations include failure to disclose a significant shift of clients to a new platform by a top DSP buyer, resulting in reduced ad spend and revenue for PubMatic [2]. - Defendants' positive statements about the company's business were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Snap Inc. (NYSE: SNAP) - The class period for Snap is from April 29, 2025, to August 5, 2025, with a lead plaintiff deadline of October 20, 2025 [3]. - The complaint alleges that Snap's optimistic reports on advertising growth were misleading, as they relied too heavily on the company's execution capabilities [3]. - Defendants failed to disclose significant execution errors and macroeconomic challenges, leading to materially misleading statements about the company's prospects [3]. Group 3: Nutex Health Inc. (NASDAQ: NUTX) - The class period for Nutex is from August 8, 2024, to August 14, 2025, with a lead plaintiff deadline of October 21, 2025 [4]. - Allegations include engaging in a scheme to defraud insurance companies, leading to unsustainable revenue claims [4]. - The company overstated its ability to remediate internal control weaknesses, resulting in improper accounting of stock-based compensation obligations [4]. Group 4: C3.ai, Inc. (NYSE: AI) - The class period for C3.ai is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline of October 21, 2025 [6]. - The complaint alleges that the company's optimistic growth reports were misleading, relying heavily on the CEO's health and effectiveness [6]. - Defendants failed to disclose that the CEO had not sufficiently recovered to fulfill his role, leading to materially misleading statements about the company's prospects [6].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. for alleged violations of the Securities Exchange Act of 1934 and related SEC rules [1] Summary by Relevant Sections - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - Shareholders who purchased shares of C3.ai during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments [1]

Core Insights - C3.ai has acknowledged its poor performance, attributing it to ineffective sales execution and leadership changes, leading to a restructuring of its sales and services departments [1] - The company reported a significant revenue decline of 19% year-over-year in Q1, with total revenue at $70.3 million, primarily driven by a drop in software licensing revenue [2][3] - C3.ai's stock has decreased by 47% year-to-date and over 60% from its all-time high, raising concerns among investors [3] Financial Performance - In Q1, subscription revenue was $60.3 million, while software licensing revenue fell to $17.9 million, a decrease of $15.9 million sequentially [2] - The company incurred net losses of $49.8 million, equating to $0.37 per share, and reported negative free cash flow of $34.3 million [2] - C3.ai has $711.9 million in cash but continues to experience significant cash burn each quarter [2] Future Outlook - For Q2, C3.ai has guided revenue expectations between $72 million and $80 million, down from $94.3 million in the same quarter last year, with operating losses projected between $49.5 million and $57.5 million [6] - The company has withdrawn its full-year outlook, indicating substantial uncertainty about its future performance [6] Market Sentiment - Analysts have expressed negative sentiment towards C3.ai, with major firms like Morgan Stanley and J.P. Morgan issuing "Sell" recommendations and lowering target prices [8] - The stock is currently rated as a "Hold" by Wall Street, with varying opinions from analysts, including three "Strong Buy," six "Hold," and four "Strong Sell" ratings [9] Product and Competitive Position - Despite challenges, C3.ai has a robust product portfolio with over 131 enterprise AI applications and a new Agentic AI platform gaining traction [7] - However, declining sales and increasing losses have led to a lack of investor confidence in the company's ability to deliver consistent growth and profitability [10]

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud affecting investors between February 26, 2025, and August 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management made overly positive statements while concealing material adverse facts about the company's growth, particularly regarding the health of its CEO and its impact on deal closures [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [2]. - Following the announcement, C3.ai's stock price dropped from $22.13 per share to $16.47 per share, marking a decline of approximately 25.58% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, alleging that the company and its executives misled investors regarding its financial health and growth prospects, violating the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Liggett v. C3.ai, Inc., claims that C3.ai provided overly optimistic revenue projections while downplaying risks associated with CEO Thomas M. Siebel's health issues [2][3]. - The class period for the lawsuit is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline set for October 21, 2025 [2][4]. - Following a disappointing financial announcement on August 8, 2025, C3.ai's stock price dropped by more than 25% after the company lowered its revenue guidance for the fiscal year [3]. Group 2: Company Performance and Leadership Impact - C3.ai attributed its poor financial results to "reorganization with new leadership" and the health problems of CEO Thomas M. Siebel [3]. - The lawsuit emphasizes that C3.ai's public statements regarding growth and profitability were deemed "unrealistic" and overly reliant on Siebel's health and performance [2][5]. Group 3: Investor Actions - Investors who suffered significant losses during the class period are encouraged to submit their claims and may seek to serve as lead plaintiffs [2][4]. - The firm leading the investigation is focused on whether C3.ai's public statements adequately disclosed the impact of Siebel's health on the company's financial targets [5].

Core Insights - C3.ai, Inc. (AI) started fiscal 2026 with profitability concerns as non-GAAP gross margin decreased to 52%, down 1,800 basis points from 70% in the previous year, primarily due to higher initial production deployment costs and reduced revenues from demonstration licenses [1][9] - The shift towards initial production deployments (IPDs) indicates both growth potential and margin risks, with management expecting moderate gross margins in the near term as support capacity is built [2] - Subscription revenues remained strong, contributing $60.3 million, or 86% of total revenues, while liquidity is robust with $711.9 million in cash, although negative free cash flow of $34.3 million highlights ongoing investment intensity [3] Financial Performance - C3.ai's gross margin contraction reflects the challenges of scaling new deployments, impacting the path to achieving non-GAAP profitability and free cash flow [1][3] - The company’s reliance on upfront-cost-heavy IPDs contrasts with peers like Palantir and Snowflake, which are demonstrating profitable scaling with strong margins [7] - C3.ai's stock has declined 23.6% over the past three months, compared to a 6.1% decline in the industry [8] Peer Comparison - Palantir Technologies Inc. reported an adjusted gross margin of 82% in Q2 2025, enabling a 46% adjusted operating margin and robust free cash flow of $569 million [5] - Snowflake Inc. achieved a non-GAAP product gross margin of 76.4% in Q2 fiscal 2026, with a modest operating margin of 11% but strong gross margin fundamentals [6] - C3.ai's current stage of maturity, characterized by negative free cash flow and moderated gross margins, places it at a disadvantage compared to peers with proven operating models [7] Valuation and Estimates - C3.ai trades at a forward price-to-sales ratio of 7.86X, significantly lower than the industry average of 17.20X [11] - The Zacks Consensus Estimate for C3.ai's fiscal 2026 earnings per share (EPS) indicates a year-over-year decline of 224.4%, while fiscal 2027 EPS is expected to rise by 23.7% [12]